Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib for Immune Skin Conditions in Down Syndrome
NCT04246372Phase 2Completed
- Sponsor
- University of Colorado Denver
- Start
- Oct 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tofacitinib oral solution in alopecia areata, atopic dermatitis (AD), hidradenitis suppurativa (HS), psoriasis, Vitiligo, sponsored by University of Colorado Denver. Started Oct 2020; status: completed.
02
Drugs
tofacitinib oral solution
03
Conditions
alopecia areataatopic dermatitis (AD)hidradenitis suppurativa (HS)psoriasisVitiligo
Beyond the preview
Go deeper on NCT04246372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04246372.